PUBBLICAZIONI

[mkdf_section_title position=”” show_separator=”yes” separator_position=”center” title_tag=”” disable_break_words=”no” title=”Pubblicazioni 2019″ holder_padding=”13px”]

Treatment and Long-Term Clinical Outcomes of Incidental Pulmonary Embolism in Patients With Cancer: An International Prospective Cohort Study.

Kraaijpoel N, Bleker SM, Meyer G, Mahé I, Muñoz A, Bertoletti L, Bartels-Rutten A, Beyer-Westendorf J, Porreca E, Boulon C, van Es N, Iosub DI, Couturaud F, Biosca M, Lerede T, Lacroix P, Maraveyas A, Aggarwal A, Girard P, Büller HR, Di Nisio M; UPE investigators.

J Clin Oncol. 2019:JCO1801977. [Epub ahead of print]

Treatment of venous thromboembolism with tinzaparin in oncological patients.

Ageno W, Barni S, Di Nisio M, Falanga A, Imberti D, Labianca RF, Mantovani L.

Minerva Med. 2019;110(3):251-258.

Managing Anti-Platelet Therapy in Thrombocytopaenic Patients with Haematological Malignancy: A Multinational Clinical Vignette-Based Experiment.

Leader A, Ten Cate V, Ten Cate-Hoek AJ, Spectre G, Beckers EAM, Raanani P, Giaccherini C, Pereg D, Schouten HC, Falanga A, Ten Cate H.

Thromb Haemost. 2019;119(1):163-174.

[mkdf_section_title position=”” show_separator=”yes” separator_position=”center” title_tag=”” disable_break_words=”no” title=”Pubblicazioni 2018″ holder_padding=”13px”]

Platelet cut-off for anticoagulant therapy in thrombocytopenic patients with blood cancer and venous thromboembolism: an expert consensus.

Napolitano M, Saccullo G, Marietta M, Carpenedo M, Castaman G, Cerchiara E, Chistolini A, Contino L, De Stefano V, Falanga A, Federici AB, Rossi E, Santoro R, Siragusa S; Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) Working Party on Thrombosis and Haemostasis (see Appendix 1).

Blood Transfus. 2018:1-10

Two Missense Variants Detected in Breast Cancer Probands Preventing BRCA2-PALB2 Protein Interaction.

Caleca L, Catucci I, Figlioli G, De Cecco L, Pesaran T, Ward M, Volorio S, Falanga A, Marchetti M, Iascone M, Tondini C, Zambelli A, Azzollini J, Manoukian S, Radice P, Peterlongo P.

Front Oncol. 2018;8:480.

Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Patients with Lung Adenocarcinoma at Risk for Cancer-Associated Thrombosis: The Observational ROADMAP-CAT Study.

Syrigos K, Grapsa D, Sangare R, Evmorfiadis I, Larsen AK, Van Dreden P, Boura P, Charpidou A, Kotteas E, Sergentanis TN, Elalamy I, Falanga A, Gerotziafas GT.

Oncologist. 2018;23(11):1372-1381.

Soluble stroma-related biomarkers of pancreatic cancer.

Resovi A, Bani MR, Porcu L, Anastasia A, Minoli L, Allavena P, Cappello P, Novelli F, Scarpa A, Morandi E, Falanga A, Torri V, Taraboletti G, Belotti D, Giavazzi R.

EMBO Mol Med. 2018;10(8). pii: e8741

Acute promyelocytic leukemia cell adhesion to vascular endothelium is reduced by heparins.

Vignoli A, Marchetti M, Falanga A.

Ann Hematol. 2018 Sep;97(9):1555-1562.

Hemostatic biomarkers in cancer progression.

Falanga A, Marchetti M.

Thromb Res. 2018 Apr;164 Suppl 1:S54-S61.

Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding.

Boriani G, Corradini P, Cuneo A, Falanga A, Foà R, Gaidano G, Ghia PP, Martelli M, Marasca R, Massaia M, Mauro FR, Minotti G, Molica S, Montillo M, Pinto A, Tedeschi A, Vitolo U, Zinzani PL.

Hematol Oncol. 2018;36(4):624-632.

Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism.

Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, Grosso MA, Kakkar AK, Kovacs MJ, Mercuri MF, Meyer G, Segers A, Shi M, Wang TF, Yeo E, Zhang G, Zwicker JI, Weitz JI, Büller HR; Hokusai VTE Cancer Investigators.

N Engl J Med. 2018;378(7):615-624.

[mkdf_section_title position=”” show_separator=”yes” separator_position=”center” title_tag=”” disable_break_words=”no” title=”Pubblicazioni 2017″ holder_padding=”13px”]

Mechanisms and risk factors of thrombosis in cancer.

Falanga A, Russo L, Milesi V, Vignoli A.

Crit Rev Oncol Hematol. 2017;118:79-83.

Long Term Low Molecular Weight Heparin Anticoagulant Therapy Modulates Thrombin Generation and D-dimer in Patients with Cancer and Venous Thromboembolism.

D’Alessio A, Marchetti M, Tartari CJ, Russo L, Cecchini S, Lambregts KWFM, di Mauro D, Falanga A.

Cancer Invest. 2017;35(7):490-499.

Predicting APL lethal bleeding in the ATRA era.

Falanga A.

Blood. 2017;129(13):1739-1740.

[mkdf_section_title position=”” show_separator=”yes” separator_position=”center” title_tag=”” disable_break_words=”no” title=”Pubblicazioni 2016″ holder_padding=”13px”]

Italian daily platelet transfusion practice for haematological patients undergoing high dose chemotherapy with or without stem cell transplantation: a survey by the GIMEMA Haemostasis and Thrombosis Working Party.

Tagariello G, Castaman G, Falanga A, Santoro R, Napolitano M, Storti S, Veneri D, Basso M, Candiotto L, Tassinari C, Federici AB, De Stefano V; GIMEMA Haemostasis and Thrombosis working party.

Blood Transfus. 2016 Nov;14(6):521-526.

Thrombophilic status may predict prognosis in patients with metastatic BRAFV600-mutated melanoma who are receiving BRAF inhibitors.

Falanga A, Marchetti M, Massi D, Merelli B, Verzeroli C, Russo L, Rulli E, Tondini C, Legramandi L, Nassini R, Scatena C, De Logu F, Cattaneo L, Mandalà M.

J Am Acad Dermatol. 2016;74(6):1254-1256.e4.

A Validated Risk Score for Venous Thromboembolism Is Predictive of Cancer Progression and Mortality.

Kuderer NM, Culakova E, Lyman GH, Francis C, Falanga A, Khorana AA.

Oncologist. 2016;21(7):861-7.

Molecular biomarkers of thrombosis in myeloproliferative neoplasms.

Barbui T, Falanga A.

Thromb Res. 2016;140 Suppl 1:S71-5.

Hypercoagulation screening as an innovative tool for risk assessment, early diagnosis and prognosis in cancer: the HYPERCAN study.

Falanga A, Santoro A, Labianca R, De Braud F, Gasparini G, D’Alessio A, Barni S, Iacoviello L; HYPERCAN Study Group.

Thromb Res. 2016;140 Suppl 1:S55-9.

[mkdf_section_title position=”” show_separator=”yes” separator_position=”center” title_tag=”” disable_break_words=”no” title=”Pubblicazioni 2015″ holder_padding=”13px”]

Cancer Tissue Procoagulant Mechanisms and the Hypercoagulable State of Patients with Cancer.

Falanga A, Schieppati F, Russo D.

Semin Thromb Hemost. 2015;41(7):756-64.

The mechanisms of cancer-associated thrombosis.

Falanga A, Marchetti M, Russo L.

Thromb Res. 2015;135 Suppl 1:S8-S11.

Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update.

Lyman GH, Bohlke K, Falanga A; American Society of Clinical Oncology.

J Oncol Pract. 2015;11(3):e442-4.

Management of cancer-associated disseminated intravascular coagulation: guidance from the SSC of the ISTH: reply.

Thachil J, Falanga A, Levi M, Liebman H, Di Nisio M.

J Thromb Haemost. 2015;13(7):1352-3.

Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis.

Schulman S, Zondag M, Linkins L, Pasca S, Cheung YW, de Sancho M, Gallus A, Lecumberri R, Molnar S, Ageno W, Le Gal G, Falanga A, Hulegårdh E, Ranta S, Kamphuisen P, Debourdeau P, Rigamonti V, Ortel TL, Lee A.

J Thromb Haemost. 2015;13(6):1010-8.

Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014.

Lyman GH, Bohlke K, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP, Clarke JM, Flowers CR, Francis CW, Gates LE, Kakkar AK, Key NS, Levine MN, Liebman HA, Tempero MA, Wong SL, Somerfield MR, Falanga A; American Society of Clinical Oncology.

J Clin Oncol. 2015;33(6):654-6.

Management of cancer-associated disseminated intravascular coagulation: guidance from the SSC of the ISTH.

Thachil J, Falanga A, Levi M, Liebman H, Di Nisio M; Scientific and Standardization Committee of the International Society on Thrombosis and Hemostasis.

J Thromb Haemost. 2015;13(4):671-5.

FANCM c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor.

Peterlongo P, Catucci I, Colombo M, Caleca L, Mucaki E, Bogliolo M, Marin M, Damiola F, Bernard L, Pensotti V, Volorio S, Dall’Olio V, Meindl A, Bartram C, Sutter C, Surowy H, Sornin V, Dondon MG, Eon-Marchais S, Stoppa-Lyonnet D, Andrieu N, Sinilnikova OM; GENESIS, Mitchell G, James PA, Thompson E; kConFab; SWE-BRCA, Marchetti M, Verzeroli C, Tartari C, Capone GL, Putignano AL, Genuardi M, Medici V, Marchi I, Federico M, Tognazzo S, Matricardi L, Agata S, Dolcetti R, Della Puppa L, Cini G, Gismondi V, Viassolo V, Perfumo C, Mencarelli MA, Baldassarri M, Peissel B, Roversi G, Silvestri V, Rizzolo P, Spina F, Vivanet C, Tibiletti MG, Caligo MA, Gambino G, Tommasi S, Pilato B, Tondini C, Corna C, Bonanni B, Barile M, Osorio A, Benitez J, Balestrino L, Ottini L, Manoukian S, Pierotti MA, Renieri A, Varesco L, Couch FJ, Wang X, Devilee P, Hilbers FS, van Asperen CJ, Viel A, Montagna M, Cortesi L, Diez O, Balmaña J, Hauke J, Schmutzler RK, Papi L, Pujana MA, Lázaro C, Falanga A, Offit K, Vijai J, Campbell I, Burwinkel B, Kvist A, Ehrencrona H, Mazoyer S, Pizzamiglio S, Verderio P, Surralles J, Rogan PK, Radice P.

Hum Mol Genet. 2015;24(18):5345-55.

[mkdf_section_title position=”” show_separator=”yes” separator_position=”center” title_tag=”” disable_break_words=”no” title=”Pubblicazioni 2014″ holder_padding=”13px”]

The coagulopathy of cancer.

Falanga A, Russo L, Milesi V.

Curr Opin Hematol. 2014;21(5):423-9.

7th international conference on thrombosis and hemostasis issues in cancer. Preface.

Falanga A, Brenner B, Rickles FR.

Thromb Res. 2014;133 Suppl 2:ix.

Thrombosis in myeloproliferative neoplasms.

Falanga A, Marchetti M.

Semin Thromb Hemost. 2014;40(3):348-58.

PALB2 sequencing in Italian familial breast cancer cases reveals a high-risk mutation recurrent in the province of Bergamo.

Catucci I, Peterlongo P, Ciceri S, Colombo M, Pasquini G, Barile M, Bonanni B, Verderio P, Pizzamiglio S, Foglia C, Falanga A, Marchetti M, Galastri L, Bianchi T, Corna C, Ravagnani F, Bernard L, Fortuzzi S, Sardella D, Scuvera G, Peissel B, Manoukian S, Tondini C, Radice P.

Genet Med. 2014;16(9):688-94.

Phospholipid-dependent procoagulant activity is highly expressed by circulating microparticles in patients with essential thrombocythemia.

Marchetti M, Tartari CJ, Russo L, Panova-Noeva M, Leuzzi A, Rambaldi A, Finazzi G, Woodhams B, Falanga A.

Am J Hematol. 2014;89(1):68-73.

[mkdf_section_title position=”” show_separator=”yes” separator_position=”center” title_tag=”” disable_break_words=”no” title=”Pubblicazioni 2013″ holder_padding=”13px”]

Myeloproliferative neoplasms and thrombosis.

Barbui T, Finazzi G, Falanga A.

Blood. 2013;122(13):2176-84.

.

ADP-induced platelet aggregation and thrombin generation are increased in Essential Thrombocythemia and Polycythemia Vera.

Panova-Noeva M, Marchetti M, Russo L, Tartari CJ, Leuzzi A, Finazzi G, Rambaldi A, ten Cate H, Falanga A.

Thromb Res. 2013;132(1):88-93.

Thrombosis and cancer: emerging data for the practicing oncologist.

Lyman GH, Khorana AA, Falanga A.

Am Soc Clin Oncol Educ Book. 2013.

Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update.

Lyman GH, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP, Clarke JM, Flowers CR, Francis CW, Gates LE, Kakkar AK, Key NS, Levine MN, Liebman HA, Tempero MA, Wong SL, Prestrud AA, Falanga A; American Society of Clinical Oncology Clinical Practice.

J Clin Oncol. 2013;31(17):2189-204.

Tissue Factor Expression on Platelet Surface during Preparation and Storage of Platelet Concentrates.

Vignoli A, Giaccherini C, Marchetti M, Verzeroli C, Gargantini C, Da Prada L, Giussani B, Falanga A.

Transfus Med Hemother. 2013;40(2):126-32.

Mechanisms of thrombosis in cancer.

Falanga A, Russo L, Verzeroli C.

Thromb Res. 2013;131 Suppl 1:S59-62

Coagulation and cancer: biological and clinical aspects.

Falanga A, Marchetti M, Vignoli A.

J Thromb Haemost. 2013;11(2):223-33.

International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer.

Debourdeau P, Farge D, Beckers M, Baglin C, Bauersachs RM, Brenner B, Brilhante D, Falanga A, Gerotzafias GT, Haim N, Kakkar AK, Khorana AA, Lecumberri R, Mandala M, Marty M, Monreal M, Mousa SA, Noble S, Pabinger I, Prandoni P, Prins MH, Qari MH, Streiff MB, Syrigos K, Büller HR, Bounameaux H.

J Thromb Haemost. 2013;11(1):71-80.

International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer.

Farge D, Debourdeau P, Beckers M, Baglin C, Bauersachs RM, Brenner B, Brilhante D, Falanga A, Gerotzafias GT, Haim N, Kakkar AK, Khorana AA, Lecumberri R, Mandala M, Marty M, Monreal M, Mousa SA, Noble S, Pabinger I, Prandoni P, Prins MH, Qari MH, Streiff MB, Syrigos K, Bounameaux H, Büller HR.

J Thromb Haemost. 2013 Jan;11(1):56-70.

[mkdf_section_title position=”” show_separator=”yes” separator_position=”center” title_tag=”” disable_break_words=”no” title=”Pubblicazioni 2012″ holder_padding=”13px”]

Thrombotic disease in the myeloproliferative neoplasms.

Falanga A, Marchetti M.

Hematology Am Soc Hematol Educ Program. 2012;2012:571-81.

Venous thromboembolism in the hematologic malignancies.

Falanga A, Marchetti M, Russo L.

Curr Opin Oncol. 2012 Nov;24(6):702-10.

Comparative assessment of low-molecular-weight heparins in cancer from the perspective of patient outcomes and survival.

Falanga A, Vignoli A, Diani E, Marchetti M.

Patient Relat Outcome Meas. 2011 Jul;2:175-88

6th International Conference on Thrombosis and Hemostasis Issues in Cancer. Preface.

Falanga A, Brenner B, Rickles FR.

Thromb Res. 2012 Apr;129 Suppl 1:ix.

Microparticles in tumor progression.

Falanga A, Tartari CJ, Marchetti M.

Thromb Res. 2012 Apr;129 Suppl 1:S132-6.

Platelet-mediated proteolytic down regulation of the anticoagulant activity of protein S in individuals with haematological malignancies.

Dienava-Verdoold I, Marchetti MR, te Boome LC, Russo L, Falanga A, Koene HR, Mertens K, Brinkman HJ.

Thromb Haemost. 2012 Mar;107(3):468-76.

Anticancer treatment and thrombosis.

Falanga A, Marchetti M.

Thromb Res. 2012; 129(3):353-9.

Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines.

Mandalà M, Falanga A, Roila F; ESMO Guidelines Working Group.

Ann Oncol. 2011;22 Suppl 6:vi85-92

Epidemiology, risk and outcomes of venous thromboembolism in cancer.

Falanga A, Russo L.

Hamostaseologie. 2012;32(2):115-25.

Prevention of venous thromboembolism in patients with cancer: guidelines of the Italian Society for Haemostasis and Thrombosis (SISET)(1).

Siragusa S, Armani U, Carpenedo M, Falanga A, Fulfaro F, Imberti D, Laurora R, Molinari AC, Prisco D, Silingardi M, Verso M, Visonà A; Italian Society for Haemostasis and Thrombosis.

Thromb Res. 2012;129(5):e171-6.

Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.

Larocca A, Cavallo F, Bringhen S, Di Raimondo F, Falanga A, Evangelista A, Cavalli M, Stanevsky A, Corradini P, Pezzatti S, Patriarca F, Cavo M, Peccatori J, Catalano L, Carella AM, Cafro AM, Siniscalchi A, Crippa C, Petrucci MT, Yehuda DB, Beggiato E, Di Toritto TC, Boccadoro M, Nagler A, Palumbo A.

Blood. 2012 Jan 26;119(4):933-9; quiz 1093.

[mkdf_section_title position=”” show_separator=”yes” separator_position=”center” title_tag=”” disable_break_words=”no” title=”Pubblicazioni 2011″ holder_padding=”13px”]

Pathogenesis and treatment of thrombohemorrhagic diathesis in acute promyelocytic leukemia.

Falanga A, Russo L, Tartari CJ.

Mediterr J Hematol Infect Dis. 2011;3(1):e2011068.

JAK2V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients.

Panova-Noeva M, Marchetti M, Buoro S, Russo L, Leuzzi A, Finazzi G, Rambaldi A, Ottomano C, Ten Cate H, Falanga A.

Blood. 2011;118(9):2599-601.

Defining the thrombotic risk in patients with myeloproliferative neoplasms.

Vianello F, Battisti A, Cella G, Marchetti M, Falanga A.

ScientificWorldJournal. 2011;11:1131-7.

All trans-retinoic acid modulates the procoagulant activity of human breast cancer cells.

Marchetti M, Russo L, Balducci D, Falanga A.

Thromb Res. 2011;128(4):368-74.

LMWH bemiparin and ULMWH RO-14 reduce the endothelial angiogenic features elicited by leukemia, lung cancer, or breast cancer cells.

Vignoli A, Marchetti M, Russo L, Cantalino E, Diani E, Bonacina G, Falanga A.

Cancer Invest. 2011;29(2):153-61.

[mkdf_section_title position=”” show_separator=”yes” separator_position=”center” title_tag=”” disable_break_words=”no” title=”Pubblicazioni 2010″ holder_padding=”13px”]

Treatment of thromboembolism in cancer patients.

Panova-Noeva M, Falanga A.

Expert Opin Pharmacother. 2010;11(12):2049-58

PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma.

Perry JR, Julian JA, Laperriere NJ, Geerts W, Agnelli G, Rogers LR, Malkin MG, Sawaya R, Baker R, Falanga A, Parpia S, Finch T, Levine MN.

J Thromb Haemost. 2010;8(9):1959-65.

Venous thromboembolism in cancer patients: ESMO Clinical Practice Guidelines for the management.

Mandalà M, Falanga A, Roila F; ESMO Guidelines Working Group.

Ann Oncol. 2010;21 Suppl 5:v274-6.

Nitric oxide derivatives and soluble plasma selectins in patients with myeloproliferative neoplasms.

Cella G, Marchetti M, Vianello F, Panova-Noeva M, Vignoli A, Russo L, Barbui T, Falanga A.

Thromb Haemost. 2010;104(1):151-6.

Prospective study of hemostatic alterations in children with acute lymphoblastic leukemia.

Giordano P, Molinari AC, Del Vecchio GC, Saracco P, Russo G, Altomare M, Perutelli P, Crescenzio N, Santoro N, Marchetti M, De Mattia D, Falanga A.

Am J Hematol. 2010;85(5):325-30.

Acquired and inherited risk factors for developing venous thromboembolism in cancer patients receiving adjuvant chemotherapy: a prospective trial.

Mandalà M, Barni S, Prins M, Labianca R, Tondini C, Russo L, Milesi A, Cremonesi M, Zaccanelli M, Regonesi C, Moro C, Falanga A.

Ann Oncol. 2010;21(4):871-6.

[mkdf_section_title position=”” show_separator=”yes” separator_position=”center” title_tag=”” disable_break_words=”no” title=”Pubblicazioni 2009″ holder_padding=”13px”]

Venous thromboembolism in the hematologic malignancies.

Falanga A, Marchetti M.

J Clin Oncol. 2009;27(29):4848-57.

Treatment of venous thromboembolism in patients with cancer: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET).

Imberti D, Di Nisio M, Donati MB, Falanga A, Ghirarduzzi A, Guarneri D, Piovella F, Santoro RC, Baldini E, Zampogna S; Italian Society for Thrombosis and Haemostasis.

Thromb Res. 2009;124(5):e32-40.

Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action.

Khorana AA, Streiff MB, Farge D, Mandala M, Debourdeau P, Cajfinger F, Marty M, Falanga A, Lyman GH.

J Clin Oncol. 2009;27(29):4919-26.

Management of venous thromboembolism in cancer patients: ESMO clinical recommendations.

Mandalà M, Falanga A, Roila F; ESMO Guidelines Working Group.

Ann Oncol. 2009;20 Suppl 4:182-4

Elevated procoagulant microparticles expressing endothelial and platelet markers in essential thrombocythemia.

Trappenburg MC, van Schilfgaarde M, Marchetti M, Spronk HM, ten Cate H, Leyte A, Terpstra WE, Falanga A.

Haematologica. 2009;94(7):911-8.

Thrombosis associated with angiogenesis inhibitors.

Elice F, Rodeghiero F, Falanga A, Rickles FR.

Best Pract Res Clin Haematol. 2009;22(1):115-28.

Procoagulant mechanisms in tumour cells.

Falanga A, Panova-Noeva M, Russo L.

Best Pract Res Clin Haematol. 2009;22(1):49-60.

[mkdf_section_title position=”” show_separator=”yes” separator_position=”center” title_tag=”” disable_break_words=”no” title=”Pubblicazioni 2008″ holder_padding=”13px”]

The pathophysiology of cancer and thrombosis. Summary and conclusions.

ten Cate H, Falanga A.

Pathophysiol Haemost Thromb. 2008;36(3-4):212-4.

Leukocytosis, JAK2V617F mutation, and hemostasis in myeloproliferative disorders.

Marchetti M, Falanga A.

Pathophysiol Haemost Thromb. 2008;36(3-4):148-59.

Overview of the postulated mechanisms linking cancer and thrombosis.

ten Cate H, Falanga A.

Pathophysiol Haemost Thromb. 2008;36(3-4):122-30.

Hemostatic complications of angiogenesis inhibitors in cancer patients.

Elice F, Jacoub J, Rickles FR, Falanga A, Rodeghiero F.

Am J Hematol. 2008;83(11):862-70.

Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation.

Landolfi R, Di Gennaro L, Falanga A.

Leukemia. 2008;22(11):2020-8.

Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera.

Marchetti M, Castoldi E, Spronk HM, van Oerle R, Balducci D, Barbui T, Rosing J, Ten Cate H, Falanga A.

Blood. 2008;112(10):4061-8.

Hypercoagulability and tissue factor gene upregulation in hematologic malignancies.

Falanga A, Barbui T, Rickles FR.

Semin Thromb Hemost. 2008;34(2):204-10.

Management of venous thromboembolism in cancer patients: ESMO clinical recommendations.

Mandalà M, Falanga A, Roila F; ESMO Guidelines Working Group.

Ann Oncol. 2008;19 Suppl 2:ii126-7.

Endothelial capillary tube formation and cell proliferation induced by tumor cells are affected by low molecular weight heparins and unfractionated heparin.

Marchetti M, Vignoli A, Russo L, Balducci D, Pagnoncelli M, Barbui T, Falanga A.

Thromb Res. 2008;121(5):637-45.

[mkdf_section_title position=”” show_separator=”yes” separator_position=”center” title_tag=”” disable_break_words=”no” title=”Pubblicazioni 2007″ holder_padding=”13px”]

Management of Thrombohemorrhagic Syndromes (THS) in hematologic malignancies.

Falanga A, Rickles FR.

Hematology Am Soc Hematol Educ Program. 2007:165-71.

Heparin in tumor progression and metastatic dissemination.

Falanga A, Marchetti M.

Semin Thromb Hemost. 2007;33(7):688-94.

V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules.

Falanga A, Marchetti M, Vignoli A, Balducci D, Russo L, Guerini V, Barbui T.

Exp Hematol. 2007 Sep;35(9):1476.

American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer.

Lyman GH, Khorana AA, Falanga A, Clarke-Pearson D, Flowers C, Jahanzeb M, Kakkar A, Kuderer NM, Levine MN, Liebman H, Mendelson D, Raskob G, Somerfield MR, Thodiyil P, Trent D, Francis CW; American Society of Clinical Oncology.

J Clin Oncol. 2007;25(34):5490-505.

[mkdf_section_title position=”” show_separator=”yes” separator_position=”center” title_tag=”” disable_break_words=”no” title=”Pubblicazioni 2006″ holder_padding=”13px”]

Anticoagulants and cancer survival.

Piccioli A, Falanga A, Prandoni P.

Semin Thromb Hemost. 2006;32(8):810-3.

Cancer and venous thromboembolism.

Piccioli A, Falanga A, Baccaglini U, Marchetti M, Prandoni P.

Semin Thromb Hemost. 2006;32(7):694-9.

Venous thromboembolism and cancer: guidelines of the Italian Association of Medical Oncology (AIOM).

Mandalà M, Falanga A, Piccioli A, Prandoni P, Pogliani EM, Labianca R, Barni S; working group AIOM.

Crit Rev Oncol Hematol. 2006;59(3):194-204.

 

Mandalà M, Falanga A, Cremonesi M, Zaccanelli M, Floriani I, Viganò MG, Rosti A, Cazzaniga ME, Ferretti G, Cabiddu M, Barni S.

Thromb Haemost. 2006;95(4):752-4.